{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:11:33Z","timestamp":1776474693171,"version":"3.51.2"},"reference-count":34,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":3059,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:p>Narcolepsy, a rare disease with a prevalence of 0.05% in the general population, affects an estimated 140,000 patients in the United States. Patients have been able to lead fuller personal and professional lives since the Food and Drug Administration approved sodium oxybate (Xyrem) in 2002 for treatment of cataplexy in patients with narcolepsy. Previously, \u03b3\u2010hydroxybutyrate (GHB), the active ingredient of sodium oxybate, had been a substance of abuse, most notoriously as a date\u2010rape drug. Public Law 106\u2013172, the date\u2010rape prohibition act enacted in 2000, was modified to allow the drug to be legally administered for medical purposes. Because of the apprehension regarding the risk of possible drug diversion after the approval of sodium oxybate and concerns about safety, the Xyrem Risk Management Program was created. This program has been successful in satisfying the needs of patients and physicians while ensuring responsible distribution of the drug.<\/jats:p>","DOI":"10.1592\/phco.23.10.1205.32756","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T05:48:28Z","timestamp":1084513708000},"page":"1205-1209","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["From Club Drug to Orphan Drug: Sodium Oxybate (Xyrem) for the Treatment of Cataplexy"],"prefix":"10.1002","volume":"23","author":[{"given":"David E.","family":"Fuller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl S.","family":"Hornfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.2.254.34110"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.20.1486.34472"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004691-200103000-00002"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)63126-1"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70440-8"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(05)70273-5"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/25.1.50"},{"key":"e_1_2_1_9_2","first-page":"77","article-title":"Validation of a cataplexy questionnaire in 983 sleep\u2010disorder patients","volume":"22","author":"Anic\u2010Labat S.","year":"1999","journal-title":"Sleep"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-83387-8_3"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1826"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)00058-1"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn808"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81969-8"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05582-8"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/79690"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199605060-00003"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(64)90074-7"},{"key":"e_1_2_1_19_2","first-page":"334","article-title":"\u03b3\u2010Hydroxybutyrate: a new metabolite in brain [abstr]","volume":"22","author":"Bessman SP","year":"1963","journal-title":"FASEB J"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(96)00064-0"},{"key":"e_1_2_1_21_2","volume-title":"\u03b3\u2010Hydroxybutyric acid [press release]","author":"Food and Drug Administration.","year":"1990"},{"key":"e_1_2_1_22_2","first-page":"447","article-title":"Multistate outbreak of poisonings associated with illicit use of \u03b3\u2010hydroxy butyrate","volume":"256","author":"Centers for Disease Control.","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(98)70231-8"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/23.3.141"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(99)00163-8"},{"issue":"49","key":"e_1_2_1_26_2","first-page":"13235","article-title":"Schedules of controlled substances: addition of \u03b3\u2010hydroxybutyric acid to schedule I","volume":"65","year":"2000","journal-title":"Federal Register"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100119304"},{"key":"e_1_2_1_28_2","first-page":"222","article-title":"The effects and effectiveness of \u03b3\u2010hydroxybutyrate in patients with narcolepsy","volume":"46","author":"Scharf M.","year":"1985","journal-title":"J Clin Psych"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198902000-00004"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/13.6.479"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/16.3.216"},{"key":"e_1_2_1_32_2","first-page":"42","article-title":"A randomized, double\u2010blind, placebo\u2010controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","author":"U. S. Xyrem Multicenter Study Group.","year":"2002","journal-title":"Sleep"},{"key":"e_1_2_1_33_2","volume-title":"Xyrem physician's monograph","author":"Orphan Medical, Inc.","year":"2002"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120019128"},{"key":"e_1_2_1_35_2","first-page":"31","article-title":"A 12\u2010month, open\u2010label, multi\u2010center extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","author":"U. S. Xyrem Multicenter Study Group.","year":"2003","journal-title":"Sleep"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.23.10.1205.32756","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.23.10.1205.32756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:55:40Z","timestamp":1761065740000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.23.10.1205.32756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1592\/phco.23.10.1205.32756"],"URL":"https:\/\/doi.org\/10.1592\/phco.23.10.1205.32756","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}